Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine Biosciences names Sanjay Keswani chief medical officer, effective June 2, 2025

Neutral Impact 3 of 5 leadership Written later

Neurocrine Biosciences said Sanjay Keswani, M.D. will succeed Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025. Dr. Roberts, who has held the role for seven years, will stay on as Strategic Advisor to the CEO through December 31, 2025 under an amended employment agreement with a $731,400 base salary.

Key points

  • Sanjay Keswani, M.D. succeeds Eiry W. Roberts, M.D. as Chief Medical Officer effective June 2, 2025
  • Dr. Roberts becomes Strategic Advisor to the CEO through December 31, 2025, with a $731,400 annual base salary
  • Dr. Roberts's target bonus is 60% of base pay for calendar year 2025; severance and outstanding equity awards carry over

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECMay 30, 2025, 4:05 PM ET
Accession number0000914475-25-000139

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.